Israel - English - Ministry of Health

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Israel - English - Ministry of Health

novartis israel ltd - octreotide - powder and solvent for suspension for injection - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin glucose; mannitol - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: mannitol; polyglactin glucose - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 10 mg - injection, modified release - excipient ingredients: mannitol; polyglactin glucose - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - octreotide -

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - octreotide acetate - solution for injection - octreotide acetate 200 µg/ml - pituitary and hypothalamic hormones and analogues

Malta - English - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - octreotide acetate - solution for injection - octreotide acetate 500 µg/ml - pituitary and hypothalamic hormones and analogues

Malta - English - Medicines Authority

central procurement & supplies unit - octreotide - solution for injection - octreotide 0.2 milligram(s)/millilitre - pituitary and hypothalamic hormones and analogues